Journal article

Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use

Margs S Brennan, Catherine Chang, Lin Tai, Guillaume Lessene, Andreas Strasser, Grant Dewson, Gemma L Kelly, Marco J Herold

Blood | AMER SOC HEMATOLOGY | Published : 2018

Grants

Awarded by Australian National Health and Medical Research Council


Awarded by Leukemia & Lymphoma Society of America


Awarded by Cancer Council of Victoria


Awarded by Victorian Cancer Agency fellowship


Awarded by Australian Government Independent Research Institute Infrastructure Support Scheme


Funding Acknowledgements

This work was supported by the Australian National Health and Medical Research Council (project grant 1145728 [M.J.H.], 1143105 [M.J.H. and A.S.], 1086291 [G.L.K.], program grant 1016701 [A.S.], and fellowship 1020363 [A.S.]), the Leukemia & Lymphoma Society of America (LLS SCOR 7001-13 [A. S. and M.J.H.]), the Cancer Council of Victoria (1086157 and 1147328 [G.L.K.], 1052309 [A. S.], and Venture Grant [M.J.H. and A. S.]), a Victorian Cancer Agency fellowship (MCRF17028 [G.L.K.]), a Leukaemia Foundation Postgraduate Award (M.S.B.), and a Grant in Aid (A. S. and G.L.K.), sponsored research funding from Servier, bequests from the Estate of Antony Redstone and the Craig Perkins Cancer Research Foundation (A. S. and G.L.K.) as well as by operational infrastructure grants through the Australian Government Independent Research Institute Infrastructure Support Scheme (9000220) and the Victorian State Government Operational Infrastructure Support Program.